Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder

BJU International

Volumn 106, Issue 8, 2010, Pages 1216-1222

  Bolenz, Christian ^a,c   Shariat, Shahrokh F ^a,b   Karakiewicz, Pierre I ^d   Ashfaq, Raheela ^a   Ho, Richard ^a   Sagalowsky, Arthur I ^a   Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

bladder cancer; HER 2; immunohistochemistry; microarray analysis; prognosis; treatment protocols

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; COHORT ANALYSIS; CORRELATION ANALYSIS; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SCORING SYSTEM; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CYSTECTOMY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 77957135510     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09190.x     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008 58 : 71 96
2. Shariat SF, Karakiewicz PI, Palapattu GS et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006 176 : 2414 22
3. Sternberg CN, de Mulder PH, Schornagel JH et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol, 30924. J Clin Oncol 2001 19 : 2638 46
4. Bellmunt J, Albiol S, Suarez C, Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol 2009 69 : 211 22
5. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000 19 : 3159 67
6. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001 61 (Suppl. 2 1 13
7. Jimenez RE, Hussain M, Bianco FJ Jr. et al. Her-2neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001 7 : 2440 7
8. Kruger S, Weitsch G, Buttner H et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 2002 102 : 514 8
9. Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996 155 : 321 6
10. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990 5 : 953 62
11. Sato K, Moriyama M, Mori S et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992 70 : 2493 8
12. Wester K, Sjostrom A, de la Torre M, Carlsson J, Malmstrom PU. HER-2 - a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 2002 41 : 282 8
13. de Pinieux G, Colin D, Vincent- Salomon A et al. Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2 neu (c-erbb-2) status in urothelial carcinoma. Virchows Arch 2004 444 : 415 9
14. Latif Z, Watters AD, Dunn I, Grigor KM, Underwood MA, Bartlett JM. HER2neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 2003 89 : 1305 9
15. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001 7 : 1957 62
16. Kassouf W, Black PC, Tuziak T et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 2008 179 : 353 8
17. Liedberg F, Anderson H, Chebil G et al. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol 2008 26 : 17 24
18. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994 81 : 515 9
19. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol 2008 18 : 1 8
20. Therasse P, Carbonnelle S, Bogaerts J. Clinical trials design and treatment tailoring: general principles applied to breast cancer research. Crit Rev Oncol Hematol 2006 59 : 98 105
21. Burstein HJ, Harris LN, Marcom PK et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003 21 : 2889 95
22. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005 353 : 1659 72
23. Spencer KS, Graus-Porta D, Leng J, Hynes NE, Klemke RL. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol 2000 148 : 385 97
24. Gardmark T, Wester K, De la Torre M, Carlsson J, Malmstrom PU. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 2005 95 : 982 6
25. Hansel DE, Swain E, Dreicer R, Tubbs RR. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am J Clin Pathol 2008 130 : 274 81
26. Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM. HER2neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004 40 : 56 63
27. Zhau HE, Zhang X, von Eschenbach AC et al. Amplification and expression of the c-erb B-2neu proto-oncogene in human bladder cancer. Mol Carcinog 1990 3 : 254 7
28. Gandour-Edwards R, Lara PN Jr., Folkins AK et al. Does HER2neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002 95 : 1009 15
29. Kolla SB, Seth A, Singh MK et al. Prognostic significance of Her2neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 2008 40 : 321 7
30. Lipponen P, Eskelinen M, Syrjanen S, Tervahauta A, Syrjanen K. Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol 1991 20 : 238 42
31. Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007 25 : 2218 24
32. Salzberg M, Borner M, Bauer JA, Morant R, Rauch D, Rochlitz C. Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. Eur J Cancer 2006 42 : 2660 1
33. Hauser-Kronberger C, Peham K, Grall J, Rausch W, Hutarew G, Dietze O. Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder. J Urol 2006 175 : 875 80